14 Acute Myeloid Leukemia Clinical Trials in Miami, FL (2026)

Q: How do I join a clinical trial in Miami?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Miami research site will contact you.

Recruiting Acute Myeloid Leukemia Studies in Miami

NCT05237258Recruiting

Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia

This research study is evaluating whether primary palliative care is an alternative strategy to specialty palliative care for improving quality of life, symptoms, mood, coping, and end of life outcome...

Miami, FLNA2,300 participantsMassachusetts General Hospital

View Study Details

NCT07007312Recruiting

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

Ziftomenib is an investigational drug in development for the treatment of patients with acute myeloid leukemia (AML) with eligible genetic alterations. Ziftomenib is a type of therapy known to target ...

Miami, FLPHASE31,300 participantsKura Oncology, Inc.

View Study Details

NCT04256317Recruiting

A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)

Study ASTX030-01 is a multi-phase study comprising of Phases 1-3 Monotherapy arms and a Phase 1 Combination Therapy arm Phase 1 Monotherapy consists of an open-label Dose Escalation Stage (Stage A) us...

Miami, FLPHASE2316 participantsTaiho Oncology, Inc.

View Study Details

NCT06788756Recruiting

L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML

This pivotal phase 2/3, multi-center, adaptive design study of L-Annamycin for Injection in combination with Cytarabine Injection as second line therapy for remission induction in adult subjects with ...

Miami, FLPHASE2312 participantsMoleculin Biotech, Inc.

View Study Details

NCT02074839Recruiting

Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation

The purpose of this Phase I, multicenter study is to evaluate the safety, pharmacokinetics, pharmacodynamics and clinical activity of AG-120 in advanced hematologic malignancies that harbor an IDH1 mu...

Miami, FLPHASE1291 participantsInstitut de Recherches Internationales Servier

View Study Details

NCT03850574Recruiting

Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia

The main purpose of this study is to identify a safe and potentially effective dose of tuspetinib to be used in future studies in study participants diagnosed with acute myeloid leukemia (AML), myelod...

Miami, FLPHASE1240 participantsAptose Biosciences Inc.

View Study Details

NCT06672146Recruiting

Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)

This phase II MyeloMATCH treatment trial studies how well ASTX727 and venetoclax plus enasidenib works compared to ASTX727 and venetoclax alone for the treatment of older patients with newly diagnosed...

Miami, FLPHASE293 participantsNational Cancer Institute (NCI)

View Study Details

NCT05857969Recruiting

Ex Vivo Drug Sensitivity Testing and Multi-Omics Profiling

Functional precision medicine (FPM) is a relatively new approach to cancer therapy based on direct exposure of patient- isolated tumor cells to clinically approved drugs and integrates ex vivo drug se...

Miami, FLPHASE165 participantsFlorida International University

View Study Details

NCT05143996Recruiting

CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

CLN-049-001 is a Phase 1, open-label, multicenter, first-in-human trial of CLN-049 in patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)...

Miami, FLPHASE160 participantsCullinan Therapeutics Inc.

View Study Details

NCT05442216Recruiting

Tagraxofusp and Azaxitadine With or Without Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents

A treatment cycle is 28 days for Cycle 1 and Cycle 2. Tagraxofusp will be administered at 12 mcg/kg IV over 15 minutes (-5 or +15 minutes) daily for 5 consecutive days (or 5 doses over a period not to...

Miami, FLPHASE253 participantsJoshua Zeidner

View Study Details

NCT06634394Recruiting

APVO436 Phase 1b/2 Study in Patients With Newly Diagnosed AML

A multi-center, open-label, dose-finding study of five dose levels of APVO436 in combination with venetoclax and azacitidine (ven/aza) in adult patients with newly diagnosed, CD123+ AML....

Miami, FLPHASE139 participantsAptevo Therapeutics

View Study Details

NCT05886049Recruiting

A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease

This phase Ib trial tests the safety, side effects, and best dose of SNDX-5613 when given in combination with the standard chemotherapy treatment (daunorubicin and cytarabine) in treating patients wit...

Miami, FLPHASE138 participantsNational Cancer Institute (NCI)

View Study Details

NCT05597306Recruiting

Venetoclax and Bomedemstat in Patients With Relapsed/Refractory Acute Myeloid Leukemia

This study aims to learn about the safety, tolerability, and different dose levels' safety profiles of Venetoclax and Bomedemstat (VenBom) combination therapy in participants with relapsed or refracto...

Miami, FLPHASE118 participantsTerrence J Bradley, MD

View Study Details

NCT06782542Recruiting

Olutasidenib, Venetoclax, and Azacitidine in IDH1 Mutated Newly Diagnosed Acute Myeloid Leukemia Patients Eligible for Intensive Induction Chemotherapy

The purpose of this study is as follows: 1. Determine whether people receiving the combination treatment of olutasidenib, venetoclax, and azacitidine have the same, more, or fewer side effects compar...

Miami, FLPHASE216 participantsJustin Watts, MD

View Study Details

About Acute Myeloid Leukemia Clinical Trials in Miami

Acute myeloid leukemia (AML) is a fast-growing cancer of the blood and bone marrow characterized by abnormal myeloid cells. It is the most common acute leukemia in adults. Treatment typically includes intensive chemotherapy and may involve stem cell transplant.

There are currently 14 acute myeloid leukemia clinical trials recruiting participants in Miami, FL. These studies are seeking a combined 5,141 participants. Research is being sponsored by Massachusetts General Hospital, Kura Oncology, Inc., Taiho Oncology, Inc. and 10 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Acute Myeloid Leukemia Clinical Trials in Miami — FAQ

Are there acute myeloid leukemia clinical trials in Miami?

Yes, there are 14 acute myeloid leukemia clinical trials currently recruiting in Miami, FL. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Miami?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Miami research site will contact you about next steps.

Are clinical trials in Miami free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Miami studies also compensate for your time and travel.

What acute myeloid leukemia treatments are being tested?

The 14 active trials in Miami are testing new therapies including novel drugs, biologics, and treatment approaches for acute myeloid leukemia.

Data updated October 18, 2026 from ClinicalTrials.gov